KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Land & Improvements (2017 - 2018)

Historic Land & Improvements for Alnylam Pharmaceuticals (ALNY) over the last 2 years, with Q4 2018 value amounting to $9.1 million.

  • Alnylam Pharmaceuticals' Land & Improvements changed 0.0% to $9.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $9.1 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $9.1 million for FY2018, which is 0.0% changed from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Land & Improvements of $9.1 million as of Q4 2018, which was down 0.0% from $9.1 million recorded in Q4 2017.
  • In the past 5 years, Alnylam Pharmaceuticals' Land & Improvements ranged from a high of $9.1 million in Q4 2017 and a low of $9.1 million during Q4 2017